home All News open_in_new Full Article

BMS pagará hasta 9.780 millones a BioNTech por un anticancerígeno

La farmacéutica estadounidense Bristol-Myers Squibb (BMS) pagará un máximo de 11.100 millones de dólares (9.780 millones de euros) al laboratorio alemán BioNTech para codesarrollar y comercializar un fármaco anticancerígeno de nueva generación (BNT327). El medicamento está en fase de ensayo, pero ha mostrado resultados prometedores hasta el momento. Leer


today 7 d. ago attach_file Science

attach_file Society
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Society


ID: 3084703118
Add Watch Country

arrow_drop_down